| dc.contributor.author | Yazici, Yusuf | |
| dc.contributor.author | Hatemi, Gülen | |
| dc.date.accessioned | 2021-03-05T20:54:20Z | |
| dc.date.available | 2021-03-05T20:54:20Z | |
| dc.date.issued | 2017 | |
| dc.identifier.citation | Hatemi G., Yazici Y., "Apremilast for the treatment of Behcet's syndrome", EXPERT OPINION ON ORPHAN DRUGS, cilt.5, ss.677-681, 2017 | |
| dc.identifier.issn | 2167-8707 | |
| dc.identifier.other | av_d6622dbb-6f85-4557-a3bc-599c46819329 | |
| dc.identifier.other | vv_1032021 | |
| dc.identifier.uri | http://hdl.handle.net/20.500.12627/141478 | |
| dc.identifier.uri | https://doi.org/10.1080/21678707.2017.1356716 | |
| dc.description.abstract | Introduction: Mucocutaneous lesions can be disabling in Behcet's syndrome patients who experience these lesions frequently and can be an important cause of impaired quality of life. Apremilast may be a safe and effective alternative for the treatment of oral and genital ulcers in Behcet's syndrome. | |
| dc.language.iso | eng | |
| dc.subject | Eczacılık | |
| dc.subject | Temel Bilimler | |
| dc.subject | Temel Eczacılık Bilimleri | |
| dc.subject | Yaşam Bilimleri | |
| dc.subject | Sağlık Bilimleri | |
| dc.subject | Yaşam Bilimleri (LIFE) | |
| dc.subject | Farmakoloji ve Toksikoloji | |
| dc.subject | FARMAKOLOJİ VE ECZACILIK | |
| dc.title | Apremilast for the treatment of Behcet's syndrome | |
| dc.type | Makale | |
| dc.relation.journal | EXPERT OPINION ON ORPHAN DRUGS | |
| dc.contributor.department | New York University , , | |
| dc.identifier.volume | 5 | |
| dc.identifier.issue | 8 | |
| dc.identifier.startpage | 677 | |
| dc.identifier.endpage | 681 | |
| dc.contributor.firstauthorID | 67212 | |
